Ad
related to: solid lipid nanoparticles cancer treatment guidelines for patients
Search results
Results from the WOW.Com Content Network
Development of solid lipid nanoparticles is one of the emerging fields of lipid nanotechnology (for a review on lipid nanotechnology, see [17]) with several potential applications in drug delivery, clinical medicine and research, as well as in other disciplines. Due to their unique size-dependent properties, lipid nanoparticles can possibly ...
Traditionally, LNPs are composed of four indispensable lipid components: an ionizable amino lipid that aids in both escaping the endosomes and binding nucleic acids to the particle, an amphipathic phospholipid that promotes fusion with the target cell and endosomes, cholesterol to enhance nanoparticle stability, and a polyethylene glycol lipid ...
In prostate cancer, the androgen receptor (AR) plays a critical role in progression of the cancer. Lipid nanoparticles (LNPs) are being considered for delivering siRNA to silence AR. The most effective LNP to be found in vivo contains an ionizable cationic lipid 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA). [4]
When the blood vessels form so rapidly, large fenestrae result that are 100 to 600 nanometers in size, which allows enhanced nanoparticle entry. Further, the poor lymphatic drainage means that the large influx of nanoparticles are rarely leaving, thus, the tumor retains more nanoparticles for successful treatment to take place. [8]
It can be directed to the location of cancer cells with sustained release behavior. Studies have also been done on gold nanoparticle responses to local near-infrared (NIR) light as a stimuli for drug release. In one study, gold nanoparticles functionalized with double-stranded DNA encapsulated with drug molecules, were irradiated with NIR light.
Drug delivery systems, lipid-[18] or polymer-based nanoparticles, can be designed to improve the pharmacokinetics and biodistribution of the drug. [19] [20] [21] However, the pharmacokinetics and pharmacodynamics of nanomedicine is highly variable among different patients. [22]
This distinction must be made by both the treating physicians and the cancer patients themselves. Many oncologists in their daily clinical practice follow their patients' malignant disease by means of repeated imaging studies and make decisions about continuing therapy on the basis of both objective and symptomatic criteria.
Lipid based nanovectors are excellent for delivering siRNA to solid tumors, [40] but other cancers may require different non-lipid based organic nanovectors such as cyclodextrin based nanoparticles. [40] [43] siRNAs delivered via lipid based nanoparticles have been shown to have therapeutic potential for central nervous system (CNS) disorders. [44]
Ad
related to: solid lipid nanoparticles cancer treatment guidelines for patients